| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AUTHOR INDEX
|
|
|
|
22 |
S |
p. S199-S223
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
22 |
S |
p. i-iii
|
artikel
|
| 3 |
NS-001: Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma
|
Aronson, Elizabeth
|
|
|
22 |
S |
p. S195
|
artikel
|
| 4 |
NS-003: Development of a nursing care pathway for monitoring pneumocystis pneumonia risk in relapsed refractory multiple myeloma
|
Bellerive, Carrie
|
|
|
22 |
S |
p. S196
|
artikel
|
| 5 |
NS-004: Increasing clinical trial accrual of minority patients by expanding clinical operations at satellite sites: a nursing lead initiative
|
Catamero, Donna
|
|
|
22 |
S |
p. S196-S197
|
artikel
|
| 6 |
NS-006: Minimal residual disease in myeloma: a patient’s perspective
|
Correia, Nuno Pedro Ferreira
|
|
|
22 |
S |
p. S197-S198
|
artikel
|
| 7 |
NS-005: The Cleveland Clinic Survivor Care Program Model for patients living with multiple myeloma and plasma cell disorders
|
Faiman, Beth
|
|
|
22 |
S |
p. S197
|
artikel
|
| 8 |
NS-007: Using feedback to understand and improve the experience of myeloma patients in the UK
|
Morris, Monica
|
|
|
22 |
S |
p. S198
|
artikel
|
| 9 |
NS-002: Value-based care: engaging myeloma patients in the selection of patient reported outcome measures
|
Beer, Hayley
|
|
|
22 |
S |
p. S195-S196
|
artikel
|
| 10 |
OAB-048: An interim analysis of a phase I/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: AMaRC 19-02 BelaCarD study
|
Lasica, Masa
|
|
|
22 |
S |
p. S29-S30
|
artikel
|
| 11 |
OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma
|
Jakubowiak, Andrzej
|
|
|
22 |
S |
p. S6
|
artikel
|
| 12 |
OAB-006: BCMA CAR T-cells secreting IL-12 to alter the tumour microenvironment in multiple myeloma
|
Lindo, Lorenzo
|
|
|
22 |
S |
p. S4
|
artikel
|
| 13 |
OAB-040: BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
|
Palacios, Juan José Lahuerta
|
|
|
22 |
S |
p. S24-S25
|
artikel
|
| 14 |
OAB-035: Characterising risk and biology Of smouldering myeloma for early detection of symptomatic myeloma: COSMOS, a prospective observational study in smouldering myeloma
|
Ainley, Louise
|
|
|
22 |
S |
p. S21
|
artikel
|
| 15 |
OAB-014: Chemotherapy signatures reveal the evolutionary history of post-melphalan myeloid neoplasm
|
Diamond, Benjamin
|
|
|
22 |
S |
p. S9
|
artikel
|
| 16 |
OAB-043: Ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma and early relapse after initial therapy: biological correlative analyses and updated clinical results from CARTITUDE-2 Cohort B
|
Agha, Mounzer
|
|
|
22 |
S |
p. S26
|
artikel
|
| 17 |
OAB-047: Clinical and translational results of the myeloma developing regimens using genomics (MyDRUG) sub-protocol C1 targeting RAS mutations
|
Kumar, Shaji
|
|
|
22 |
S |
p. S29
|
artikel
|
| 18 |
OAB-054: Comparative efficacy of teclistamab versus real-world physician’s choice of therapy in the prospective LocoMMotion study in patients with triple-class exposed relapsed/refractory multiple myeloma
|
van de Donk, Niels W.C.J.
|
|
|
22 |
S |
p. S33-S34
|
artikel
|
| 19 |
OAB-041: Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04
|
Touzeau, Cyrille
|
|
|
22 |
S |
p. S25
|
artikel
|
| 20 |
OAB-046: Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
|
Hajek, Roman
|
|
|
22 |
S |
p. S28-S29
|
artikel
|
| 21 |
OAB-037: Detection of abnormal plasma cells by multiparameter flow cytometry in a screened cohort of patients with monoclonal gammopathy of undetermined significance
|
Óskarsson, Jón Þórir
|
|
|
22 |
S |
p. S22
|
artikel
|
| 22 |
OAB-027: Discovery of tumor-reactive T cell receptors in multiple myeloma
|
Kehl, Niklas
|
|
|
22 |
S |
p. S16
|
artikel
|
| 23 |
OAB-012: Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival
|
Paiva, Bruno
|
|
|
22 |
S |
p. S7-S8
|
artikel
|
| 24 |
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma
|
Zonder, Jeffrey
|
|
|
22 |
S |
p. S35
|
artikel
|
| 25 |
OAB-008: Efficacy and safety of BCMA-targeted CAR-T therapy in elderly patients with multiple myeloma
|
Reyes, Kevin
|
|
|
22 |
S |
p. S5
|
artikel
|
| 26 |
OAB-044: Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting antibody-drug conjugate treatment
|
Cohen, Adam
|
|
|
22 |
S |
p. S26-S27
|
artikel
|
| 27 |
OAB-062: Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting bispecific antibody treatment
|
San-Miguel, Jesus
|
|
|
22 |
S |
p. S35-S36
|
artikel
|
| 28 |
OAB-034: External validation of the simplified score to predict early relapse in multiple myeloma (S-ERMM) in the MMRF CoMMpass dataset
|
Slade, Michael
|
|
|
22 |
S |
p. S20-S21
|
artikel
|
| 29 |
OAB-018: From CARDAMON to CoMMpass: a mutational signature that predicts carfilzomib-specific outcomes in myeloma
|
Walker, Ieuan
|
|
|
22 |
S |
p. S11-S12
|
artikel
|
| 30 |
OAB-021: High-risk multiple myeloma due to extramedullary disease-like gene expression induced by bone marrow stromal cells
|
Binder, Moritz
|
|
|
22 |
S |
p. S13
|
artikel
|
| 31 |
OAB-016: High risk subclones detected at relapse are present from diagnosis in small subclones and impact the prognosis
|
Lannes, Romain
|
|
|
22 |
S |
p. S10
|
artikel
|
| 32 |
OAB-026: Humoral immune reconstitution after quadruplet therapy, autologous hematopoietic cell transplant (AHCT) and measurable residual disease adapted treatment cessation in newly diagnosed myeloma (NDMM)
|
Gowda, Sonia
|
|
|
22 |
S |
p. S15-S16
|
artikel
|
| 33 |
OAB-004: Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: real-world experience
|
Hansen, Doris
|
|
|
22 |
S |
p. S2-S3
|
artikel
|
| 34 |
OAB-032: Identification of myeloma-initiating cells and novel therapeutic target by single-cell sequencing
|
Gong, Lixin
|
|
|
22 |
S |
p. S19
|
artikel
|
| 35 |
OAB-049: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)–related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
|
Popat, Rakesh
|
|
|
22 |
S |
p. S30
|
artikel
|
| 36 |
OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
|
Richardson, Paul
|
|
|
22 |
S |
p. S32
|
artikel
|
| 37 |
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
|
Richardson, Paul
|
|
|
22 |
S |
p. S33
|
artikel
|
| 38 |
OAB-017: Mutations accumulated before and after hyperdiploidy reveal timing and impact of chromosomal gains on multiple myeloma
|
Smits, Thomas
|
|
|
22 |
S |
p. S10-S11
|
artikel
|
| 39 |
OAB-003: Phase 1 study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma
|
Frigault, Matthew
|
|
|
22 |
S |
p. S2
|
artikel
|
| 40 |
OAB-031: PHF19 promotes multiple myeloma cell resistant to daratumumab/isatuximab via upregulation in immunosuppressive microenvironment and reduced CD38 target expression
|
Yu, Tengteng
|
|
|
22 |
S |
p. S18-S19
|
artikel
|
| 41 |
OAB-038: Physiotherapist-led exercise prehabilitation embedded within the multiple myeloma autologous stem cell transplantation pathway: a feasibility randomised controlled trial
|
McCourt, Orla
|
|
|
22 |
S |
p. S23
|
artikel
|
| 42 |
OAB-005: Point mutations in BCMA extracellular domain mediate resistance to BCMA targeting immune therapies
|
Lee, Holly
|
|
|
22 |
S |
p. S3-S4
|
artikel
|
| 43 |
OAB-001: Potentiating T cell activity against multiple myeloma through SUMOylation inhibition
|
Du, Li
|
|
|
22 |
S |
p. S1
|
artikel
|
| 44 |
OAB-033: Pre-clinical models of genetically heterogeneous multiple myeloma reveal mechanisms of immune escape and predict clinical immunotherapy outcomes
|
Larrayoz, Marta
|
|
|
22 |
S |
p. S19-S20
|
artikel
|
| 45 |
OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial
|
D’Agostino, Mattia
|
|
|
22 |
S |
p. S6-S7
|
artikel
|
| 46 |
OAB-019: Proteogenomic screens reveal that RAS commandeers the amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
|
Yang, Yandan
|
|
|
22 |
S |
p. S12
|
artikel
|
| 47 |
OAB-020: RAD51 interacts with minichromosome maintenance protein complex (MCM2–7) providing strong dependency in myeloma
|
Zhao, Jiangning
|
|
|
22 |
S |
p. S12
|
artikel
|
| 48 |
OAB-050: Randomized phase 2 study of weekly carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple (MM) patients (GEMKyCyDex)
|
Puertas, Borja
|
|
|
22 |
S |
p. S30-S31
|
artikel
|
| 49 |
OAB-051: Salvage therapies and clinical outcomes after relapse following BCMA CAR-T in patients with relapsed/refractory multiple myeloma
|
Reyes, Kevin
|
|
|
22 |
S |
p. S31-S32
|
artikel
|
| 50 |
OAB-009: γ-secretase inhibitors augment efficacy of BCMA-targeting T cell engagers against multiple myeloma cells without impairing T cell effector function
|
Tai, Yu-Tzu
|
|
|
22 |
S |
p. S5-S6
|
artikel
|
| 51 |
OAB-023: Single-cell analysis reveals disease induced perturbations of CD8+T-cell subsets in the bone marrow and peripheral blood of newly diagnosed multiple myeloma patients
|
Favaloro, James
|
|
|
22 |
S |
p. S14
|
artikel
|
| 52 |
OAB-028: Single-cell dissection of bone marrow and peripheral blood immune cells in a large cohort of patients with smoldering multiple myeloma at diagnosis and post-therapy
|
Sklavenitis-Pistofidis, Romanos
|
|
|
22 |
S |
p. S16-S17
|
artikel
|
| 53 |
OAB-015: Single cell multiomic analysis reveals relapsed and refractory multiple myeloma clusters associated with 1q alterations and overexpression of PHF19 that are present at diagnosis in high-risk patients
|
Johnson, Travis
|
|
|
22 |
S |
p. S9-S10
|
artikel
|
| 54 |
OAB-030: Single-cell RNA-seq reveals XBP1-SLC38A2 axis as a player in immunosuppressive T lymphocytes in multiple myeloma
|
Wan, Yike
|
|
|
22 |
S |
p. S18
|
artikel
|
| 55 |
OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy
|
Tahri, Sabrin
|
|
|
22 |
S |
p. S17-S18
|
artikel
|
| 56 |
OAB-024: T cell differentiation in the bone marrow during disease evolution: insights from COSMOS and integrative analysis of 317,000 single-cell transcriptomes
|
Foster, Kane
|
|
|
22 |
S |
p. S14-S15
|
artikel
|
| 57 |
OAB-042: The impact of marginalization on treatment receipt and overall survival in newly diagnosed multiple myeloma patients in Ontario: a population-based cohort study
|
Visram, Alissa
|
|
|
22 |
S |
p. S25-S26
|
artikel
|
| 58 |
OAB-036: The PANGEA model: dynamic modeling for personalized prediction of precursor disease progression to multiple myeloma
|
Cowan, Annie
|
|
|
22 |
S |
p. S21-S22
|
artikel
|
| 59 |
OAB-002: The preexisting T cell landscape determines response to T cell-engagers therapy in multiple myeloma
|
Friedrich, Mirco
|
|
|
22 |
S |
p. S1-S2
|
artikel
|
| 60 |
OAB-022: The role of bone marrow adipocyte-modulated aryl hydrocarbon receptor activity in multiple myeloma cellular growth and survival
|
Diedrich, Jonathan
|
|
|
22 |
S |
p. S13-S13a
|
artikel
|
| 61 |
OAB-025: The role of checkpoint inhibitor PD-1H/VISTA in osteoclast activation and bone disease in multiple myeloma
|
Fu, Jing
|
|
|
22 |
S |
p. S15
|
artikel
|
| 62 |
OAB-039: Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study
|
Moreau, Philippe
|
|
|
22 |
S |
p. S23-S24
|
artikel
|
| 63 |
OAB-013: Universal loss of BCL7A allows release of its binding partner IRF4 inducing its transcriptional activity promoting MM cell growth
|
Chakraborty, Chandraditya
|
|
|
22 |
S |
p. S8
|
artikel
|
| 64 |
OAB-007: Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma
|
Raje, Noopur
|
|
|
22 |
S |
p. S4-S5
|
artikel
|
| 65 |
OAB-045: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy: CARTITUDE-2 Cohort A
|
Cohen, Adam
|
|
|
22 |
S |
p. S27-S28
|
artikel
|
| 66 |
OAB-055: Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma
|
Voorhees, Peter
|
|
|
22 |
S |
p. S34
|
artikel
|
| 67 |
P-110: Activity and tolerability of lenalidomide (LLD) is enhanced following low-dose continuous percutaneous delivery compared to once daily dosing in an NCIH929 MM Xenograft model in SCID mice
|
Oliver, Jamie
|
|
|
22 |
S |
p. S95-S96
|
artikel
|
| 68 |
P-103: ADAR1-dsRNA metabolism in myeloma cells with 1q amplification: a novel therapeutic target
|
Harada, Takeshi
|
|
|
22 |
S |
p. S92
|
artikel
|
| 69 |
P-236: Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: switching from doublet to triplet
|
Cerchione, Claudio
|
|
|
22 |
S |
p. S165
|
artikel
|
| 70 |
P-282: Addition of ixazomib to pomalidomide-dexamethasone improves progression-free survival for myeloma patients progressing on frontline lenalidomide: results of the randomized alliance study A061202
|
Voorhees, Peter
|
|
|
22 |
S |
p. S193
|
artikel
|
| 71 |
P-247: Addressing the knowledge gap to optimize treatment sequencing for patients with relapsed/refractory multiple myeloma
|
Heller, Elizabeth
|
|
|
22 |
S |
p. S171-S172
|
artikel
|
| 72 |
P-281: Adjusted comparison of teclistamab versus physician’s choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma
|
Mateos, María-Victoria
|
|
|
22 |
S |
p. S192-S193
|
artikel
|
| 73 |
P-047: ADVANCE multicenter clinical trial: MRD-driven therapy in newly diagnosed multiple myeloma patients
|
Landgren, Ola
|
|
|
22 |
S |
p. S61
|
artikel
|
| 74 |
P-232: Adverse event patterns and management with pomalidomide, dexamethasone, and daratumumab in patients with relapsed or refractory multiple myeloma: a safety analysis of the phase 2 MM-014 study
|
Bahlis, Nizar
|
|
|
22 |
S |
p. S162-S163
|
artikel
|
| 75 |
P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
|
Kumar, Shaji
|
|
|
22 |
S |
p. S37-S38
|
artikel
|
| 76 |
P-171: African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients
|
Akhlaghi, Theresia
|
|
|
22 |
S |
p. S129
|
artikel
|
| 77 |
P-039: African American race as potential favourable biologic factor impacts clinical outcome for patients with multiple myeloma
|
Kort, Jeries
|
|
|
22 |
S |
p. S57
|
artikel
|
| 78 |
P-197: A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: carinae study
|
de la Fuente, Felipe de Arriba
|
|
|
22 |
S |
p. S143-S144
|
artikel
|
| 79 |
P-100: Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma
|
Ferguson, Ian
|
|
|
22 |
S |
p. S90
|
artikel
|
| 80 |
P-079: Altered composition of CD8 T cells subsets over time in the bone marrow of multiple myeloma patients with long- and short-term disease control
|
Behsen, Alenka
|
|
|
22 |
S |
p. S78-S79
|
artikel
|
| 81 |
P-168: A multicenter prospective study for validation of the Korean Simple Geriatric Assessment Tool in elderly patients with multiple myeloma
|
Lee, Ji Yun
|
|
|
22 |
S |
p. S127
|
artikel
|
| 82 |
P-108: An antisense platform for the pre-clinical development of novel LncRNA inhibitors in multiple myeloma
|
Morelli, Eugenio
|
|
|
22 |
S |
p. S94-S95
|
artikel
|
| 83 |
P-038: An atlas of the bone marrow bone proteome of patients with dysproteinemias
|
Ho, Matthew
|
|
|
22 |
S |
p. S56-S56a
|
artikel
|
| 84 |
P-097: A novel anti-BCMA lipid-based nanoparticle for multiple myeloma therapy
|
Al-Ahmady, Zahraa
|
|
|
22 |
S |
p. S88-S89
|
artikel
|
| 85 |
P-112: Anti-BCMA therapy in multiple myeloma: a single-center experience
|
Puertas, Borja
|
|
|
22 |
S |
p. S96-S97
|
artikel
|
| 86 |
P-206: Antibodies to omicron variants are maintained in newly diagnosed MM patients on lenalidomide, cyclophosphamide, bortezomib and dexamethasone (RCyBorD): results from the UK RADAR/Myeloma XV Trial
|
Asher, Samir
|
|
|
22 |
S |
p. S148-S149
|
artikel
|
| 87 |
P-086: Antitumor activity of activated marrowinfiltrating lymphocytes in patients with multiple myeloma
|
Lee, Je-Jung
|
|
|
22 |
S |
p. S82-S83
|
artikel
|
| 88 |
P-107: Anti-tumor activity of covalent menin inhibitor, BMF-219, in high-grade B-cell lymphoma and multiple myeloma preclinical models
|
Lu, Daniel
|
|
|
22 |
S |
p. S94
|
artikel
|
| 89 |
P-257: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma: EXCALIBER-RRMM
|
Lonial, Sagar
|
|
|
22 |
S |
p. S177-S178
|
artikel
|
| 90 |
P-178: A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels
|
Shah, Urvi
|
|
|
22 |
S |
p. S133
|
artikel
|
| 91 |
P-070: A pleiotropy scan on multiple myeloma survival
|
Macauda, Angelica
|
|
|
22 |
S |
p. S73-S74
|
artikel
|
| 92 |
P-248: A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in 295 Japanese patients with relapsed/refractory multiple myeloma
|
Iino, Masaki
|
|
|
22 |
S |
p. S172
|
artikel
|
| 93 |
P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
|
Silvennoinen, Raija
|
|
|
22 |
S |
p. S157
|
artikel
|
| 94 |
P-011: A randomized phase 2 study of modakafusp alfa (TAK-573) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with a pilot diversity, equity, and inclusion (DEI) strategy
|
Kaufman, Jonathan
|
|
|
22 |
S |
p. S42
|
artikel
|
| 95 |
P-031: Artificial intelligence analysis of whole-body magnetic resonance imaging of patients with multiple myeloma to find prognostic factors
|
Morita, Kento
|
|
|
22 |
S |
p. S52-S53
|
artikel
|
| 96 |
P-228: ASCT does not benefit patients who are MRD negative following induction therapy: updated results from the Phase 2 Cardamon study
|
Yong, Kwee
|
|
|
22 |
S |
p. S160-S161
|
artikel
|
| 97 |
P-181: Assessing the association between body mass index at diagnosis and the risk of progression in patients with monoclonal gammopathy of undetermined significance
|
Visram, Alissa
|
|
|
22 |
S |
p. S134-S135
|
artikel
|
| 98 |
P-176: Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: a retrospective study of 34 patients highlighting the need for consensus criteria
|
Pianko, Matthew J.
|
|
|
22 |
S |
p. S131-S132
|
artikel
|
| 99 |
P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
|
Charalampous, Charalampos
|
|
|
22 |
S |
p. S149-S150
|
artikel
|
| 100 |
P-053: A systematic review of measurable residual disease (MRD) assessment characteristics in myeloma trials from 2015-2020
|
Van Oekelen, Oliver
|
|
|
22 |
S |
p. S64-S65
|
artikel
|
| 101 |
P-169: Bendamustine rituximab primary therapy for Waldenström Macroglobulinemia: an international, multicenter collaborative study
|
Zanwar, Saurabh
|
|
|
22 |
S |
p. S127-S128
|
artikel
|
| 102 |
P-275: Bendamustine therapy for advanced relapsed/refractory multiple myeloma
|
Shkury, Eden
|
|
|
22 |
S |
p. S189
|
artikel
|
| 103 |
P-231: Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial
|
Amatangelo, Michael
|
|
|
22 |
S |
p. S162
|
artikel
|
| 104 |
P-036: Bone anabolic effect of ixazomib - a third generation proteasome inhibitor – in multiple myeloma patients
|
Diaz-delCastillo, Marta
|
|
|
22 |
S |
p. S55
|
artikel
|
| 105 |
P-088: Bone marrow mesenchymal stem cells regulate the function of NK cells via TIM-3/Gal-9 in multiple myeloma
|
Liu, Zhaoyun
|
|
|
22 |
S |
p. S83-S84
|
artikel
|
| 106 |
P-084: Bone marrow of patients post ASCT, but not chemotherapy consolidation, contains expanded T cell receptor clonotypes that are present at diagnosis: results from the Phase 2 CARDAMON study
|
Foster, Kane
|
|
|
22 |
S |
p. S81-S82
|
artikel
|
| 107 |
P-190: Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
|
Meseha, Mina
|
|
|
22 |
S |
p. S139-S140
|
artikel
|
| 108 |
P-226: Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China
|
Xu, Jingyu
|
|
|
22 |
S |
p. S159-S159a
|
artikel
|
| 109 |
P-130: Brazilian ineligible multiple myeloma patients: real world data from a prospective multicenter platform
|
Crusoe, Edvan
|
|
|
22 |
S |
p. S106-S107
|
artikel
|
| 110 |
P-009: Busulfan and cyclophosphamide as a conditioning regimen for autologous transplantation in patients with multiple myeloma after treatment with proteasome inhibitors and/or immunomodulatory drugs
|
Kang, Ka-Won
|
|
|
22 |
S |
p. S41
|
artikel
|
| 111 |
P-223: Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
|
Song, Ga-Young
|
|
|
22 |
S |
p. S157-S158
|
artikel
|
| 112 |
P-214: Busulfan plus cyclophosphamide and etoposide versus high-dose melphalan as conditioning in autologous stem cell transplantation for newly diagnosed multiple myeloma
|
Lim, Sungnam
|
|
|
22 |
S |
p. S153
|
artikel
|
| 113 |
P-157: Carfilzomib (CFZ) resistance is associated with significant deregulation of the BH3 family proteins in multiple myeloma (MM)
|
Schneller, Anja
|
|
|
22 |
S |
p. S121
|
artikel
|
| 114 |
P-277: Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma
|
Tilmont, Remi
|
|
|
22 |
S |
p. S190
|
artikel
|
| 115 |
P-220: Carfilzomib-lenalidomide-dexamethasone consolidation in myeloma patients with a positive FDG PET/CT after upfront autologous stem cell transplantation: a Phase II Study (CONPET)
|
Nørgaard, Jakob Nordberg
|
|
|
22 |
S |
p. S156
|
artikel
|
| 116 |
P-075: CD200 expression in multiple myeloma is regulated by P53 and exerts its function as immune checkpoint on T cells via DOK2
|
Shah, Pooja
|
|
|
22 |
S |
p. S76
|
artikel
|
| 117 |
P-119: CDK7 is a proximal regulator of cellular functions impacting MYC-driven pathways and eliciting unique metabolic vulnerabilities in multiple myeloma
|
Yao, Yao
|
|
|
22 |
S |
p. S100-S101
|
artikel
|
| 118 |
P-012: Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM)
|
Krishnan, Amrita
|
|
|
22 |
S |
p. S42-S43
|
artikel
|
| 119 |
P-083: Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR-T therapy in myeloma
|
Dhodapkar, Kavita
|
|
|
22 |
S |
p. S80-S81
|
artikel
|
| 120 |
P-211: Changes in serum alkaline phosphatase levels during induction therapy to predict outcomes in patients with newly diagnosed multiple myeloma
|
Goel, Utkarsh
|
|
|
22 |
S |
p. S151
|
artikel
|
| 121 |
P-131: Changes in the parameters of oxidative stress in blood of patients over 50 years old with multiple myeloma after participation in a 6-week health training cycle
|
Czewińska-Ledwig, Olga
|
|
|
22 |
S |
p. S107
|
artikel
|
| 122 |
P-235: Chemo or chemo-free regimens in heavily pretreated multiple myeloma? Role of bendamustine-bortezomib-dexamethasone (BVD) in novel agents’ era
|
Cerchione, Claudio
|
|
|
22 |
S |
p. S164-S165
|
artikel
|
| 123 |
P-059: Chemotherapy-induced transcriptional reprogramming of multiple myeloma revealed by single-cell RNA sequencing
|
Chen, Mengping
|
|
|
22 |
S |
p. S68
|
artikel
|
| 124 |
P-037: Chinese herbal medicine 'Diwu’ suppresses myeloma bone disease via ERK/MAPK signalling pathway by targeting CCL3
|
He, Huiwen
|
|
|
22 |
S |
p. S56
|
artikel
|
| 125 |
P-259: Ciltacabtagene autoleucel (cilta-cel) versus real world clinical practice in triple-class exposed multiple myeloma: adjusted comparison of patient reported outcomes from CARTITUDE-1 and LocoMMotion
|
Mateos, María-Victoria
|
|
|
22 |
S |
p. S179
|
artikel
|
| 126 |
P-021: 7C6 is a novel monoclonal antibody that induces enhanced anti-myeloma activity of cytokine induced memory-like (CIML) NK cells by blocking MICA/B shedding and antibodydependent cell cytotoxicity
|
Tahri, Sabrin
|
|
|
22 |
S |
p. S47-S48
|
artikel
|
| 127 |
P-132: Clinical characteristics and infectionrelated outcomes in patients with lymphoid malignancies with or without secondary immunodeficiencies: results from a retrospective multi-database study
|
Davids, Matthew
|
|
|
22 |
S |
p. S107-S108
|
artikel
|
| 128 |
P-134: Clinical characteristics and long-term outcomes of patients with POEMS syndrome: a large academic center’s experience
|
Dima, Danai
|
|
|
22 |
S |
p. S108-S109
|
artikel
|
| 129 |
P-238: Clinical impact of time to the best response in relapsed/refractory multiple myeloma patients receiving carfilzomib
|
Cho, Hee Jeong
|
|
|
22 |
S |
p. S166
|
artikel
|
| 130 |
P-002: Clinical outcomes and effectiveness of heart transplantation in patients with systemic light-chain cardiac amyloidosis
|
Jeong, Hyehyun
|
|
|
22 |
S |
p. S37
|
artikel
|
| 131 |
P-138: Clinical profile and outcome of invasive aspergillosis in patients with myeloma: a single centre expereince from North India
|
Hasan, Faheema
|
|
|
22 |
S |
p. S111
|
artikel
|
| 132 |
P-179: Comorbidities associated with monoclonal gammopathy of undetermined significance, its subtypes, and risk factors
|
Singh, Lawanya
|
|
|
22 |
S |
p. S133-S134
|
artikel
|
| 133 |
P-024: Comparable toxicity and outcomes with generic and innovator melphalan in myeloma auto transplants
|
Devasia, Anup
|
|
|
22 |
S |
p. S49
|
artikel
|
| 134 |
P-271: Comparative effectiveness of lenalidomide/ dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States
|
Sanchez, Larysa
|
|
|
22 |
S |
p. S187
|
artikel
|
| 135 |
P-251: Comparative effectiveness of teclistamab versus real-world physician’s choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
|
Krishnan, Amrita
|
|
|
22 |
S |
p. S174
|
artikel
|
| 136 |
P-167: Comparison of frontline treatment regimens in Waldenström Macroglobulinemia – a multicentre Asian cohort
|
Tan, Jing Yuan
|
|
|
22 |
S |
p. S126-S127
|
artikel
|
| 137 |
P-015: Comprehensive comparison of allogenic CAR NK cells for MM treatment
|
Martín, Elena Maroto
|
|
|
22 |
S |
p. S44
|
artikel
|
| 138 |
P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-cel)
|
Rytlewski, Julie
|
|
|
22 |
S |
p. S46
|
artikel
|
| 139 |
P-269: COVALENT-101: a Phase 1 study of BMF-219, a novel oral covalent menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma
|
Ravandi, Farhad
|
|
|
22 |
S |
p. S185-S186
|
artikel
|
| 140 |
P-137: COVID – 19 vaccine uptake in patients with multiple myeloma and AL amyloidosis: a crosssectional observational study from India
|
Ganju, Prabhat
|
|
|
22 |
S |
p. S110
|
artikel
|
| 141 |
P-164: Daratumumab, carfilzomib, pomalidomide and elotuzumab for the treatment of poems syndrome: the Mayo Clinic experience
|
Vaxman, Iuliana
|
|
|
22 |
S |
p. S125
|
artikel
|
| 142 |
P-219: Daratumumab (DARA) + lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
|
Nooka, Ajay
|
|
|
22 |
S |
p. S155-S156
|
artikel
|
| 143 |
P-260: Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
|
Mateos, María-Victoria
|
|
|
22 |
S |
p. S179-S180
|
artikel
|
| 144 |
P-056: Deep coverage targeted next generation sequencing approach to determine somatic mutational spectrum of recurrently mutated genes in newly diagnosed multiple myeloma in a large Indian cohort
|
Basnal, Atul
|
|
|
22 |
S |
p. S66
|
artikel
|
| 145 |
P-209: Deepening responses post upfront ASCT in newly diagnosed multiple myeloma in the era of novel agent induction therapy
|
Ebraheem, Mohammad
|
|
|
22 |
S |
p. S150
|
artikel
|
| 146 |
P-050: Detecting of myeloma cell-derived MPs by flow cytometry as a potential strategy to reflect minimal residual disease in MM patients.
|
Liu, Zhaoyun
|
|
|
22 |
S |
p. S62-S63
|
artikel
|
| 147 |
P-049: Detection of multiple myeloma cell load by multiple-color flow cytometry as a useful approach for analyzing immune cell subsets in patients
|
Liu, Zhaoyun
|
|
|
22 |
S |
p. S62
|
artikel
|
| 148 |
P-065: Development of a mass cytometry-based toolkit to investigate myeloma therapeutic responses ex vivo
|
Gooding, Sarah
|
|
|
22 |
S |
p. S71
|
artikel
|
| 149 |
P-061: Differential expression profile and bioinformatic analysis of serum exosomal miRNA in multiple myeloma patients
|
Fang, Teng
|
|
|
22 |
S |
p. S68-S69
|
artikel
|
| 150 |
P-089: Disordered metabolism mediates the immunosuppressive microenvironment in multiple myeloma
|
Lv, Junqiang
|
|
|
22 |
S |
p. S84
|
artikel
|
| 151 |
P-160: Disparities in multiple myeloma between hispanics and non-hispanics – real world outcomes
|
Shaikh, Hira
|
|
|
22 |
S |
p. S123
|
artikel
|
| 152 |
P-185: Domestic opportunity in heavily pretreated multiple myeloma not eligible to hospitalbased treatment: role of pomalidomide-dexamethasone
|
Cerchione, Claudio
|
|
|
22 |
S |
p. S136-S137
|
artikel
|
| 153 |
P-005: Dual specific bivalent CS1 bispecific antibody for cellular immunotherapy against multiple myeloma
|
Awuah, Dennis
|
|
|
22 |
S |
p. S38-S39
|
artikel
|
| 154 |
P-215: D-VTd as induction therapy in newly diagnosed multiple myeloma (NDMM) patients who are candidates for transplantation: a real-life experience in a single center
|
Chamorro, Carmen Martínez
|
|
|
22 |
S |
p. S153-S153a
|
artikel
|
| 155 |
P-203: Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)
|
Oriol, Albert
|
|
|
22 |
S |
p. S146-S147
|
artikel
|
| 156 |
P-216: Early stem cell transplantation for newly diagnosed multiple myeloma in the era of novel agents: it is time to stop
|
Miles, Brittany
|
|
|
22 |
S |
p. S154
|
artikel
|
| 157 |
P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma
|
Sgherza, Nicola
|
|
|
22 |
S |
p. S122-S123
|
artikel
|
| 158 |
P-213: Efficacy and safety of bortezomib in once weekly vs. twice weekly dosing in the treatment of multiple myeloma
|
Ang, Kwan-Keat
|
|
|
22 |
S |
p. S152
|
artikel
|
| 159 |
P-272: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable proteasome inhibitor-based therapy in patients with relapsed/refractory multiple myeloma
|
Sasaki, Makoto
|
|
|
22 |
S |
p. S187-S188
|
artikel
|
| 160 |
P-242: Efficacy of selinexor in relapsed/refractory multiple myeloma (RRMM) patients with del17p and other high-risk abnormalities: a retrospective single-center study
|
Ehsan, Hamid
|
|
|
22 |
S |
p. S168-S169
|
artikel
|
| 161 |
P-280: Efficacy of thalidomide therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis
|
Vardhan, Gyan
|
|
|
22 |
S |
p. S192
|
artikel
|
| 162 |
P-279: Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial
|
van de Donk, Niels W.C.J.
|
|
|
22 |
S |
p. S191-S192
|
artikel
|
| 163 |
P-244: Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis
|
Farrell, James
|
|
|
22 |
S |
p. S169-S170
|
artikel
|
| 164 |
P-158: End-of-life treatment and treatment costs of multiple myeloma patients in a real-world setting: a retrospective analysis of 104 patients from diagnosis to death
|
Seefat, Maarten
|
|
|
22 |
S |
p. S121-S122
|
artikel
|
| 165 |
P-109: ER-phagic control of lipid metabolism supports multiple myeloma cell survival
|
Oliva, Laura
|
|
|
22 |
S |
p. S95
|
artikel
|
| 166 |
P-262: Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial
|
McGarvey, November
|
|
|
22 |
S |
p. S181
|
artikel
|
| 167 |
P-170: Evaluating serum free light chain ratio as a biomarker for multiple myeloma
|
Akhlaghi, Theresia
|
|
|
22 |
S |
p. S128-S129
|
artikel
|
| 168 |
P-156: Evaluation of SAVED and IMPEDE-VTE scoring systems for venous thromboembolism prophylaxis in patients with multiple myeloma
|
Sandifer, Christopher
|
|
|
22 |
S |
p. S120-S121
|
artikel
|
| 169 |
P-064: Evaluation of single nucleotide variants of CDKN1A, TP53BP, and XRCC1 genes in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with treatment response
|
Garrido, David
|
|
|
22 |
S |
p. S70-S71
|
artikel
|
| 170 |
P-127: Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma, a real-world analysis
|
Chen, haimin
|
|
|
22 |
S |
p. S105
|
artikel
|
| 171 |
P-071: Exonuclease 1 co-operates with a pyrimidine synthetase to drive growth and genomic instability in multiple myeloma
|
Mu, Shidai
|
|
|
22 |
S |
p. S74
|
artikel
|
| 172 |
P-095: Exosomal miR-27b-3p suppresses CD28 expression in T cells and facilitates immune escape of multiple myeloma
|
Wei, Xiaojing
|
|
|
22 |
S |
p. S87-S88
|
artikel
|
| 173 |
P-074: Exploring batch effect in single-cell data integration in a multi-center multiple myeloma immune atlas initiative
|
Pilcher, William
|
|
|
22 |
S |
p. S75-S76
|
artikel
|
| 174 |
P-010: Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
|
Karvouni, Maria
|
|
|
22 |
S |
p. S41-S41a
|
artikel
|
| 175 |
P-266: Favorable outcomes of 3-weekly daratumumab-based regimens in relapsed/refractory multiple myeloma: impact of MRD, rapid doubling time, LDH, triplets and quadruplets
|
Ngai, Cheong
|
|
|
22 |
S |
p. S184
|
artikel
|
| 176 |
P-180: 18F-FDG PET/CT can be used to predict progression in smoldering multiple myeloma patients
|
Visram, Alissa
|
|
|
22 |
S |
p. S134
|
artikel
|
| 177 |
P-217: First line daratumumab-VTd versus VRd for transplant eligible multiple myeloma
|
Byun, Ja Min
|
|
|
22 |
S |
p. S154-S154a
|
artikel
|
| 178 |
P-166: Free light chain escape: should we monitor free light chains more closely?
|
Yavuz, Boran
|
|
|
22 |
S |
p. S126
|
artikel
|
| 179 |
P-044: Genetically undetectable and negative minimal residual disease after induction therapy are equally important for survival in multiple myeloma
|
Cui, Jian
|
|
|
22 |
S |
p. S59-S60
|
artikel
|
| 180 |
P-136: Global myeloma trial participation and drug access in the era of novel therapies
|
Fatoki, Raleigh
|
|
|
22 |
S |
p. S110
|
artikel
|
| 181 |
P-123: Global quantitative lipidomic profiling of bone marrow (BM) plasma between patients with multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS)
|
Atilgan, Ezgi
|
|
|
22 |
S |
p. S103
|
artikel
|
| 182 |
P-270: GO41036: a Phase Ia/Ib open-label, multicenter study evaluating the safety and pharmacokinetics of tiragolumab in combination with atezolizumab and daratumumab in patients with R/R MM
|
Ruppert, Shannon M.
|
|
|
22 |
S |
p. S186
|
artikel
|
| 183 |
P-105: HDAC6 inhibitors enhance proteasomedependent antigen presentation to promote T-cell-mediated tumor killing
|
Kim, Byun-Gyu
|
|
|
22 |
S |
p. S93
|
artikel
|
| 184 |
P-239: Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life standard of care (SOC) treatments: results from the LocoMMotion study
|
Delforge, Michel
|
|
|
22 |
S |
p. S166-S167
|
artikel
|
| 185 |
P-014: High function, but low level stem cell memory T cells in multiple myeloma: a potential tumor targeted and long lived cell therapy population
|
Liu, Zhaoyun
|
|
|
22 |
S |
p. S43-S44
|
artikel
|
| 186 |
P-124: High protein concentration in CSF is a hallmark in multiple myeloma with CNS involvement
|
Castro-Mollo, Melanie
|
|
|
22 |
S |
p. S103-S104
|
artikel
|
| 187 |
P-117: High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma
|
Weir, Philip
|
|
|
22 |
S |
p. S99-S100
|
artikel
|
| 188 |
P-093: Iberdomide induces activation and proliferation of innate and adaptive immune cell subsets in the tumor microenvironment of relapsed/refractory myeloma patients
|
Van Oekelen, Oliver
|
|
|
22 |
S |
p. S86-S87
|
artikel
|
| 189 |
P-150: Identification of misclassified multiple myeloma patient risk subgroups with a novel biological disease stratifier
|
Panahi, Afsaneh
|
|
|
22 |
S |
p. S117-S118
|
artikel
|
| 190 |
P-066: Identification of novel driver SPANXD and preferential loss of arginine codons in multiple myeloma
|
Gupta, Ritu
|
|
|
22 |
S |
p. S71-S72
|
artikel
|
| 191 |
P-058: Identifying microRNAs as potential biomarkers of drug resistance in multiple myeloma patients: proof-of-concept study
|
Bergantim, Rui
|
|
|
22 |
S |
p. S67
|
artikel
|
| 192 |
P-175: Identifying risk factors of monoclonal gammopathy of undetermined significance (MGUS): a population-based study using data from the UK clinical practice research datalink (CPRD)
|
Koshiaris, Constantinos
|
|
|
22 |
S |
p. S131
|
artikel
|
| 193 |
P-090: Immune biomarkers of survival and infectionrelated mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
|
Maia, Catarina
|
|
|
22 |
S |
p. S84-S85
|
artikel
|
| 194 |
P-253: Impact of adjusting bortezomib dose in the pomalidomide, bortezomib, and dexamethasone (PVd) combination: a post hoc analysis of the OPTIMISMM study
|
Larocca, Alessandra
|
|
|
22 |
S |
p. S175
|
artikel
|
| 195 |
P-246: Impact of defining refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
|
Goel, Utkarsh
|
|
|
22 |
S |
p. S171
|
artikel
|
| 196 |
P-273: Impact of early relapse on survival of patients with multiple myeloma after autologous cell transplant
|
Seehaus, Cristian
|
|
|
22 |
S |
p. S188
|
artikel
|
| 197 |
P-026: Impact of monoclonal anti-CD38 antibody on collected myeloid and erythroid progenitor cells and clinical course of autologous stem cell transplant for patients with multiple myeloma
|
Manjappa, Shivaprasad
|
|
|
22 |
S |
p. S50
|
artikel
|
| 198 |
P-210: Impact of pre-transplant disease status on progression-free survival (PFS) in patients with multiple myeloma undergoing auto-HCT
|
Keshava, Vinay Edlukudige
|
|
|
22 |
S |
p. S150-S151
|
artikel
|
| 199 |
P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
|
Charalampous, Charalampos
|
|
|
22 |
S |
p. S149
|
artikel
|
| 200 |
P-153: Impact of t(11;14) in multiple myeloma on response to treatment and survival
|
Puertas, Borja
|
|
|
22 |
S |
p. S119
|
artikel
|
| 201 |
P-092: Impaired glutamine/glutamate metabolic axis into myeloma microenvironment affects osteoclast formation.
|
Toscani, Denise
|
|
|
22 |
S |
p. S86
|
artikel
|
| 202 |
P-154: Incidence and prognosis of renal failure in multiple myeloma: 50-years experience from an academic institution
|
Rosiñol, Laura
|
|
|
22 |
S |
p. S119-S120
|
artikel
|
| 203 |
P-196: In-class transition (iCT) from bortezomib (V)-based induction to oral ixazomib-lenalidomidedexamethasone vs parenteral V-based therapy: comparative effectiveness in newly diagnosed multiple myeloma
|
Costello, Caitlin
|
|
|
22 |
S |
p. S143
|
artikel
|
| 204 |
P-204: In-class transition (iCT) from parenteral bortezomib to oral ixazomib therapy in newly diagnosed multiple myeloma (NDMM) patients (pts): fully accrued data from the communitybased US MM-6 study
|
Yimer, Habte
|
|
|
22 |
S |
p. S147-S148
|
artikel
|
| 205 |
P-034: Indian multicentre phase II randomized study comparing post stem cell transplantation maintenance regimens for newly diagnosed multiple myeloma patients (IMPOSe trial)
|
Yanamandra, Uday
|
|
|
22 |
S |
p. S54
|
artikel
|
| 206 |
P-120: Indirubin-3’-monoxime acts as proteasome inhibitor: therapeutic application in multiple myeloma
|
Yu, Zhen
|
|
|
22 |
S |
p. S101-S102
|
artikel
|
| 207 |
P-113: Infectious toxicities in patients treated with bispecific antibodies in multiple myeloma
|
Saez, Adolfo
|
|
|
22 |
S |
p. S97-S98
|
artikel
|
| 208 |
P-268: INSURE: a global pooled analysis of patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with ixazomib-lenalidomidedexamethasone (IRd) in routine clinical practice
|
Ramasamy, Karthik
|
|
|
22 |
S |
p. S185
|
artikel
|
| 209 |
P-022: Intensity of cyclophosphamide-based bridging regimens before BCMA-directed CAR-T therapy
|
Zafar, Aneeqa
|
|
|
22 |
S |
p. S48
|
artikel
|
| 210 |
P-025: Investigating the effect of irreversible proteasome inhibitor carfilzomib in in vivo models of cardiometabolic syndrome and early stage HFrEFP: prophylactic role of metformin
|
Efentakis, Panagiotis
|
|
|
22 |
S |
p. S49-S50
|
artikel
|
| 211 |
P-255: Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) in real-life context: interim analysis of the retrospective IMAGE study
|
Leleu, Xavier
|
|
|
22 |
S |
p. S176-S177
|
artikel
|
| 212 |
P-041: Is there an effect of daratumumab on litics bone lesions in patients with multiple myeloma? A case report
|
Palazzo, Giulia
|
|
|
22 |
S |
p. S58
|
artikel
|
| 213 |
P-035: Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China
|
Zhuang, Zhe
|
|
|
22 |
S |
p. S54-S55
|
artikel
|
| 214 |
P-195: Lenalidomide, bortezomib, and dexamethasone (RVd) as first-line (1L) therapy in patients who are non-transplanted: results from the Connect® MM registry
|
Abonour, Rafat
|
|
|
22 |
S |
p. S142
|
artikel
|
| 215 |
P-027: Lenalidomide does not affect platelet function in vitro
|
Li, Panpan
|
|
|
22 |
S |
p. S50-S51
|
artikel
|
| 216 |
P-032: Lenalidomide maintenance after autologous hematopoetic stem cell transplantation in Hungary from 2016 to 2021
|
Lakatos, Viktor
|
|
|
22 |
S |
p. S53
|
artikel
|
| 217 |
P-101: Long noncoding RNA LINC01410 interacts with the minichromosome maintenance (MCM) complex to promote tumor cell growth in multiple myeloma
|
Gramegna, Doriana
|
|
|
22 |
S |
p. S90-S91
|
artikel
|
| 218 |
P-202: Machine learning-assisted identification of optimal first-line treatment for newly diagnosed, transplant ineligible multiple myeloma
|
Koo, Jamin
|
|
|
22 |
S |
p. S146
|
artikel
|
| 219 |
P-062: MAF translocations are enriched in high-risk NDMM patients with elevated levels of circulating tumor cells suggesting a genetic basis for the aggressive disease course
|
Fokkema, Cathelijne
|
|
|
22 |
S |
p. S69
|
artikel
|
| 220 |
P-017: MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant
|
Mateos, María-Victoria
|
|
|
22 |
S |
p. S45
|
artikel
|
| 221 |
P-046: Maintenance therapy cessation for patients with three-year sustained MRD negative remissions: initial results from a phase II study
|
Korde, Neha
|
|
|
22 |
S |
p. S60-S61
|
artikel
|
| 222 |
P-263: Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
|
Moreau, Philippe
|
|
|
22 |
S |
p. S181-S182
|
artikel
|
| 223 |
P-052: Measurable residual disease (MRD) dynamics during maintenance with ixazomib vs placebo in 1280 newly diagnosed multiple myeloma (NDMM) patients: a pooled analysis of the TOURMALINE-MM3 and -MM4 trials
|
Paiva, Bruno
|
|
|
22 |
S |
p. S63-S64
|
artikel
|
| 224 |
P-045: Minimal residual disease detected by a novel isotope labeled PET/CT combined with nextgeneration flowcytometry in newly diagnosed multiple myeloma
|
Du, Jianhua
|
|
|
22 |
S |
p. S60
|
artikel
|
| 225 |
P-096: MiR-27b-3p suppresses CD28 expression in T cells and facilitates immune escape of multiple myeloma
|
Yu, Zhen
|
|
|
22 |
S |
p. S88
|
artikel
|
| 226 |
P-055: Monitoring the emergence of multiple myeloma high-risk subclones with whole-genome sequencing of circulating tumor cells
|
Alberge, Jean-Baptiste
|
|
|
22 |
S |
p. S65-S66
|
artikel
|
| 227 |
P-163: Mortality in patients with multiple myeloma: the mylord study from the french national health data system (SNDS)
|
Touzeau, Cyrille
|
|
|
22 |
S |
p. S124-S125
|
artikel
|
| 228 |
P-182: Mosaic chromosomal alterations increase risk of incident monoclonal gammopathy of undetermined significance and multiple myeloma
|
von Beck, Kelly
|
|
|
22 |
S |
p. S135
|
artikel
|
| 229 |
P-188: Moving from research priorities to clinical research: implementing the results of a priority setting partnership on multiple myeloma
|
Fowler, Samantha
|
|
|
22 |
S |
p. S138
|
artikel
|
| 230 |
P-104: Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma
|
Huber, Julia
|
|
|
22 |
S |
p. S92-S93
|
artikel
|
| 231 |
P-077: Multiple myeloma genomic landscape explored by dimensional scaling technique highlights the presence of 1q&13+ patients with specific genomic, transcriptional and clinical features
|
Terragna, Carolina
|
|
|
22 |
S |
p. S77-S78
|
artikel
|
| 232 |
P-125: Multiple myeloma in Reunion Island: a descriptive and pronostic study on newly diagnosed patients between 2015 and 2019
|
Chane-Teng, Romain
|
|
|
22 |
S |
p. S104
|
artikel
|
| 233 |
P-133: Myeloma-induced bone pain: lessons learnt from a localized, immunocompetent mouse model
|
Diaz-delCastillo, Marta
|
|
|
22 |
S |
p. S108
|
artikel
|
| 234 |
P-054: Neoplastic plasma cells in stem cell collection have no effect on the survival of multiple myeloma patients receiving autologous stem cell transplantation
|
Xu, Jingyu
|
|
|
22 |
S |
p. S65
|
artikel
|
| 235 |
P-076: Network topology analysis reveals unique multiple myeloma genomic subtypes and potential new therapeutic targets
|
Simhal, Anish
|
|
|
22 |
S |
p. S77
|
artikel
|
| 236 |
P-221: Nicotine exposure and treatment outcomes in multiple myeloma: a retrospective cohort study
|
Puskoor, Sujith
|
|
|
22 |
S |
p. S156-S156a
|
artikel
|
| 237 |
P-102: Novel anti-CD84 humanized monoclonal antibody enhances anti-tumor immunity in multiple myeloma
|
Gunes, Metin
|
|
|
22 |
S |
p. S91
|
artikel
|
| 238 |
P-099: Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable
|
Seval, Guldane Cengiz
|
|
|
22 |
S |
p. S89-S90
|
artikel
|
| 239 |
P-081: Obesity and sarcopenia are highly prevalent in newly diagnosed multiple myeloma patients and are associated with myeloma-specific characteristics
|
dos Santos, David Cordas
|
|
|
22 |
S |
p. S79-S80
|
artikel
|
| 240 |
P-018: Optimized affinity CD38 CAR-NK cells with CD38 KO show promising in-vivo activity in a multiple myeloma model
|
O’Dwyer, Michael
|
|
|
22 |
S |
p. S45-S46
|
artikel
|
| 241 |
P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
|
Spiliopoulou, Vassiliki
|
|
|
22 |
S |
p. S123-S124
|
artikel
|
| 242 |
P-183: Outcomes in respiratory tract infections in hospitalized multiple myeloma patients with asthma and chronic obstructive pulmonary disease
|
Atodaria, Kuldeepsinh
|
|
|
22 |
S |
p. S135-S136
|
artikel
|
| 243 |
P-177: Outcomes in risk-stratified patients with smoldering multiple myeloma: a retrospective analysis of real-world data from the Czech Registry of Monoclonal Gammopathies
|
Sandecka, Viera
|
|
|
22 |
S |
p. S132-S133
|
artikel
|
| 244 |
P-201: Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomidecontaining regimens in the real world: a report from the Canadian Myeloma Research Group Database
|
Kaedbey, Rayan
|
|
|
22 |
S |
p. S145-S146
|
artikel
|
| 245 |
P-140: Outreach and satellite transplant clinics increase multiple myeloma (MM) transplant referrals and specifically transplant referrals of African American patients
|
Jillella, Anand
|
|
|
22 |
S |
p. S112
|
artikel
|
| 246 |
P-106: Overcoming IMiDs-resistance in multiple myeloma by targeting MAP4K2
|
Li, Shirong
|
|
|
22 |
S |
p. S93-S94
|
artikel
|
| 247 |
P-155: Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 49-years experience from an academic institution
|
Rosiñol, Laura
|
|
|
22 |
S |
p. S120
|
artikel
|
| 248 |
P-060: Pathogenic germline mutations in a large cohort of multiple myeloma
|
Conry, Michael
|
|
|
22 |
S |
p. S68-S68a
|
artikel
|
| 249 |
P-033: Patient multiple myeloma cells do not express targetable levels of CD38 when in remission on daratumumab
|
Reiman, Lauren
|
|
|
22 |
S |
p. S53-S54
|
artikel
|
| 250 |
P-192: Patient reported outcome & family reported outcome and the most correlated clinical measures over one year of follow-Up
|
Midlig, Kareem
|
|
|
22 |
S |
p. S140-S141
|
artikel
|
| 251 |
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
|
Susek, Katharina
|
|
|
22 |
S |
p. S46-S47
|
artikel
|
| 252 |
P-184: Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone
|
Cerchione, Claudio
|
|
|
22 |
S |
p. S136
|
artikel
|
| 253 |
P-042: Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
|
Yee, Andrew
|
|
|
22 |
S |
p. S58-S59
|
artikel
|
| 254 |
P-252: Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma
|
Kumar, Anupama
|
|
|
22 |
S |
p. S174-S175
|
artikel
|
| 255 |
P-139: Pim-2 kinase regulate the expression of TIGIT and function of NK cells from multiple myeloma patients
|
Jia, Yue
|
|
|
22 |
S |
p. S111-S111a
|
artikel
|
| 256 |
P-194: Plinabulin after autologous hematopoietic cell transplant to decrease duration of neutropenia and improve quality of life peri-transplant
|
Shah, Gunjan
|
|
|
22 |
S |
p. S141-S142
|
artikel
|
| 257 |
P-278: Post-authorization safety of lenalidomide + dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey
|
Tuğlular, Ayşe Tülin Fıratlı
|
|
|
22 |
S |
p. S190-S191
|
artikel
|
| 258 |
P-230: Preclinical and translational biomarker analysis to support further clinical development and dose optimization of mezigdomide (MEZI; CC-92480) in combination with either bortezomib or carfilzomib
|
Amatangelo, Michael
|
|
|
22 |
S |
p. S161-S162
|
artikel
|
| 259 |
P-250: Predictive factors for outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed/refractory multiple myeloma: a single-institution experience
|
Khan, Abdullah
|
|
|
22 |
S |
p. S173-S174
|
artikel
|
| 260 |
P-172: Pre-malignant plasma cells exhibit senescence features and may drive multiple myeloma tumorigenesis through LINE1-mediated genomic instability
|
Borges, Gabriel Alvares
|
|
|
22 |
S |
p. S129-S130
|
artikel
|
| 261 |
P-152: Prevalence of monoclonal gammopathies in adult Uruguayan population
|
Pérez, Lucia
|
|
|
22 |
S |
p. S118-S119
|
artikel
|
| 262 |
P-149: Prevalence of type 1 Gaucher disease in patients with multiple myeloma: interim analysis of a prospective, multicentre, observational study
|
Offidani, Massimo
|
|
|
22 |
S |
p. S116-S117
|
artikel
|
| 263 |
P-151: Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group
|
Peña, Camila
|
|
|
22 |
S |
p. S118
|
artikel
|
| 264 |
P-141: Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant
|
Kaddoura, Marcella
|
|
|
22 |
S |
p. S112-S113
|
artikel
|
| 265 |
P-173: Prognostic utility of the evolving biomarkerbased progression model (e-model) for smoldering multiple myeloma (SMM) in a diverse population
|
Atrash, Shebli
|
|
|
22 |
S |
p. S130
|
artikel
|
| 266 |
P-007: Proposed clinical factors scoring system for chimeric antigen receptor T-cell (CAR T) patient selection in relapsed and refractory multiple myeloma (RRMM)
|
Faiman, Beth
|
|
|
22 |
S |
p. S39-S40
|
artikel
|
| 267 |
P-043: Prospective assessment of myeloma tumour burden and bone disease using DW-MRI and exploratory bone biomarkers
|
Agarwal, Gaurav
|
|
|
22 |
S |
p. S59
|
artikel
|
| 268 |
P-256: Proteasome inhibition prolonged by in-class transitioned ixazomib-based regimen in newly diagnosed and first-line relapsed multiple myeloma patients in China: a real-world study
|
Liu, Aijun
|
|
|
22 |
S |
p. S177
|
artikel
|
| 269 |
P-212: Quantifying the average treatment effect of single vs. tandem autologous stem cell transplantation in newly diagnosed multiple myeloma using causal inference
|
Grieb, Nora
|
|
|
22 |
S |
p. S151-S152
|
artikel
|
| 270 |
P-193: Quantitative analysis of free light chains in multiple myeloma patients using volumetric absorptive microsampling
|
Paranthaman, Nithya
|
|
|
22 |
S |
p. S141
|
artikel
|
| 271 |
P-122: Racial differences in spinal cord compression related hospitalizations in patients with multiple myeloma: a population based study
|
Hadidi, Samer Al
|
|
|
22 |
S |
p. S102-S103
|
artikel
|
| 272 |
P-198: Real-life experience of the combination of daratumumab, bortezomib, melphalan, and prednisone (DVMP) in patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation
|
Domingo-González, Amalia
|
|
|
22 |
S |
p. S144
|
artikel
|
| 273 |
P-241: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the Flatiron database
|
Dhakal, Binod
|
|
|
22 |
S |
p. S168
|
artikel
|
| 274 |
P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database
|
Dhakal, Binod
|
|
|
22 |
S |
p. S167
|
artikel
|
| 275 |
P-234: Real-world belantamab mafodotin (belamaf) use: a US retrospective longitudinal pharmacy and medical open-source claims database assessment
|
Boytsov, Natalie
|
|
|
22 |
S |
p. S164
|
artikel
|
| 276 |
P-199: Real-world duration of use and dosing frequency of daratumumab in patients with multiple myeloma in the U.S.
|
Fonseca, Rafael
|
|
|
22 |
S |
p. S144-S145
|
artikel
|
| 277 |
P-249: Real world evidence and outcomes of patients who are exposed or refractory to lenalidomide at the time of first relapse: a Greek registry analysis
|
Kastritis, Efstathios
|
|
|
22 |
S |
p. S172-S173
|
artikel
|
| 278 |
P-218: Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and related diseases registries.
|
Ng, Justin
|
|
|
22 |
S |
p. S155
|
artikel
|
| 279 |
P-006: Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma
|
Canonico, Dalton
|
|
|
22 |
S |
p. S39
|
artikel
|
| 280 |
P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study
|
Shragai, Tamir
|
|
|
22 |
S |
p. S98
|
artikel
|
| 281 |
P-258: Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis
|
Martin, Thomas
|
|
|
22 |
S |
p. S178
|
artikel
|
| 282 |
P-245: Real-world outcomes in multiple myeloma (MM) patients who received subsequent therapy after daratumumab from the PREAMBLE study
|
Farrell, James
|
|
|
22 |
S |
p. S170
|
artikel
|
| 283 |
P-229: Real-world outcomes of sequencing elotuzumab (elo)-based regimens following daratumumab (dara) in patients with relapsed/refractory multiple myeloma: results from the Connect® MM Registry
|
Ailawadhi, Sikander
|
|
|
22 |
S |
p. S161
|
artikel
|
| 284 |
P-276: Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU cohort in France: IFM 2020-04 study
|
Talbot, Alexis
|
|
|
22 |
S |
p. S189-S190
|
artikel
|
| 285 |
P-237: Real-world treatment patterns and clinical outcomes in patients with triple-class exposed relapsed or refractory multiple myeloma in United States clinical practice
|
Chari, Ajai
|
|
|
22 |
S |
p. S165-S166
|
artikel
|
| 286 |
P-030: Regular monitoring with whole body low-dose CT for osteolysis in multiple myeloma reveals more cases of progressive bone disease than imaging performed by clinical indication
|
Gundesen, Michael
|
|
|
22 |
S |
p. S52
|
artikel
|
| 287 |
P-068: Relating subclonal mutational shifts with progression of multiple myeloma
|
Kaur, Gurvinder
|
|
|
22 |
S |
p. S72-S73
|
artikel
|
| 288 |
P-147: Renal transplant in light chain deposition disease – salvation or highway to hell? A case presentation
|
Minarik, Jiri
|
|
|
22 |
S |
p. S115-S116
|
artikel
|
| 289 |
P-121: Representation of multiple myeloma patients in the cancer genome atlas and clinical trials
|
Aggarwal, Nidhi
|
|
|
22 |
S |
p. S102
|
artikel
|
| 290 |
P-085: Resistance to immunogenic cell death as a novel mechanism of immune escape in high-risk multiple myeloma
|
Gulla, Annamaria
|
|
|
22 |
S |
p. S82
|
artikel
|
| 291 |
P-187: Retrospective review of chronic pain causes and management in multiple myeloma patients
|
Dave, Ami
|
|
|
22 |
S |
p. S137-S138
|
artikel
|
| 292 |
P-233: Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma
|
Becnel, Melody
|
|
|
22 |
S |
p. S163-S164
|
artikel
|
| 293 |
P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes
|
Chyra, Zuzana
|
|
|
22 |
S |
p. S36-S37
|
artikel
|
| 294 |
P-116: S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma
|
Wang, Yanmeng
|
|
|
22 |
S |
p. S99
|
artikel
|
| 295 |
P-013: Safety and efficacy of daratumumab-based chemoimmunotherapy in multiple myeloma or AL amyloidosis patients with advanced renal failure
|
Landau, Kevin
|
|
|
22 |
S |
p. S43
|
artikel
|
| 296 |
P-146: Screening technique for M-proteins in acetonitrile precipitates of serum using MALDITOF mass spectrometry: a comparison with serum immunofixation electrophoresis and serum free light chain assay
|
Mehra, Nikita
|
|
|
22 |
S |
p. S115
|
artikel
|
| 297 |
P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
|
Ntanasis-Stathopoulos, Ioannis
|
|
|
22 |
S |
p. S116
|
artikel
|
| 298 |
P-098: Serological proteome analysis identifying autoantibodies against tumor-associated antigen ENO1 as a potential prognostic biomarker in multiple myeloma
|
Bilkova, Zuzana
|
|
|
22 |
S |
p. S89
|
artikel
|
| 299 |
P-129: Simultaneous versus consecutive assessment of disease markers for defining progressive disease in multiple myeloma
|
Claveau, Jean-Sebastien
|
|
|
22 |
S |
p. S105-S106
|
artikel
|
| 300 |
P-073: Single-cell analysis of multiple myelomas refines bortezomib treatment responsiveness
|
Park, Sung-Soo
|
|
|
22 |
S |
p. S75
|
artikel
|
| 301 |
P-072: Single cell RNA sequencing reveals intrapatient multiple myeloma subpopulations with contrasting phenotypes and clinical behaviors
|
Ohlstrom, Denis
|
|
|
22 |
S |
p. S74-S75
|
artikel
|
| 302 |
P-087: Single-cell RNA sequencing reveals ZNF683 as a key regulator of NK cell exhaustion in multiple myeloma
|
Li, Xin
|
|
|
22 |
S |
p. S83
|
artikel
|
| 303 |
P-008: Single center, real-world, retrospective assessment of outcomes with idecabtagene vicleucel (ide-cel) for relapsed/refractory myeloma after prior treatment with a BCMA-targeted therapy
|
Ferreri, Christopher
|
|
|
22 |
S |
p. S40-S41
|
artikel
|
| 304 |
P-224: Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)
|
Villalba, Ana
|
|
|
22 |
S |
p. S158
|
artikel
|
| 305 |
P-143: SLIM CRAB criteria revisited: a meta-analysis of studies on 'biomarker defined early multiple myeloma’
|
Ludwig, Heinz
|
|
|
22 |
S |
p. S113-S114
|
artikel
|
| 306 |
P-200: Solitary pulmonary plasmacytoma: about a case
|
Jadot, Gaspard
|
|
|
22 |
S |
p. S145
|
artikel
|
| 307 |
P-082: Stromal cell - neutrophil interactions are driving a pro tumor environment in multiple myeloma
|
de Jong, Madelon
|
|
|
22 |
S |
p. S80
|
artikel
|
| 308 |
P-057: Studying microRNAs from extracellular vesicles as potential biomarkers in liquid biopsies of multiple myeloma patients
|
Bergantim, Rui
|
|
|
22 |
S |
p. S66-S67
|
artikel
|
| 309 |
P-267: Subcutaneous isatuximab administration by an on-body delivery system in combination with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: interim phase 1b study results
|
Quach, Hang
|
|
|
22 |
S |
p. S184-S185
|
artikel
|
| 310 |
P-243: Subgroup analyses from the LocoMMotion study of real-life current standard of care (SOC) in patients with relapsed/refractory multiple myeloma (RRMM)
|
Einsele, Hermann
|
|
|
22 |
S |
p. S169
|
artikel
|
| 311 |
P-004: Successful ex-plantation of left ventricular assist device after cardiac recovery with daratumumab therapy in a patient with end stage heart failure due to immunoglobulin light-chain (AL) amyloidosis
|
Tan, Daryl
|
|
|
22 |
S |
p. S38
|
artikel
|
| 312 |
P-028: Successful use of frontline daratumumab lenalidomide and dexamethasone in transplant ineligible frail patients with moderate renal failure at the time of presentation
|
Sevindik, Omur
|
|
|
22 |
S |
p. S51
|
artikel
|
| 313 |
P-023: Successful use of split dose intravenous daratumumab in an overweight multiple myeloma patient after first dose life threatening infusion-related reaction
|
Aykaş, Fatma
|
|
|
22 |
S |
p. S48-S49
|
artikel
|
| 314 |
P-051: Sustained bone marrow and imaging MRD negativity as indicators to discontinue lenalidomide maintenance after ASCT; preliminary results of a single-center prospective cohort study
|
Malandrakis, Panagiotis
|
|
|
22 |
S |
p. S63
|
artikel
|
| 315 |
P-067: Systematic functional characterization for loss of function events cooperating with TP53 loss in high-risk 17p13(del) multiple myeloma
|
Teoh, Phaik Ju
|
|
|
22 |
S |
p. S72
|
artikel
|
| 316 |
P-078: Targeted sequencing in a diverse real-world cohort of multiple myeloma patients reveals pathogenic mutations of likely germline origin in BRCA2 and other DNA damage repair genes
|
Thibaud, Santiago
|
|
|
22 |
S |
p. S78
|
artikel
|
| 317 |
P-111: Targeting the mitochondrial protease ClpP unveils novel vulnerabilities in multiple myeloma
|
Perini, Tommaso
|
|
|
22 |
S |
p. S96
|
artikel
|
| 318 |
P-029: The association of microbiota composition and proteasome inhibitor-related gastrointestinal adverse effects
|
Xialu, Ian
|
|
|
22 |
S |
p. S51-S52
|
artikel
|
| 319 |
P-165: The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria
|
Yan, Wenqiang
|
|
|
22 |
S |
p. S125-S126
|
artikel
|
| 320 |
P-145: The clinical significance of a “MGUS” tumor board
|
Mazzoni, Sandy
|
|
|
22 |
S |
p. S114-S115
|
artikel
|
| 321 |
P-094: The expression and prognostic significance of piRNA-823 in multiple myeloma
|
Wang, Dongjiao
|
|
|
22 |
S |
p. S87
|
artikel
|
| 322 |
P-186: The impact of a 6-week cycle of Nordic walking health training on the functional fitness of women with multiple myeloma
|
Czewińska-Ledwig, Olga
|
|
|
22 |
S |
p. S137
|
artikel
|
| 323 |
P-063: The independent adverse prognostic significance of 1q21 gain in newly diagnosed multiple myeloma patients
|
Fu, Chengcheng
|
|
|
22 |
S |
p. S70
|
artikel
|
| 324 |
P-080: The mosaic microenvironment of myeloma bone marrow trephine mapped by deep learning
|
Hagos, Yeman Brhane
|
|
|
22 |
S |
p. S79
|
artikel
|
| 325 |
P-069: The observed genomic instability in myeloma is driven by functional co-operation between apurinic/apyrimidinic nuclease (APEX) and RAD51
|
Liao, Chengcheng
|
|
|
22 |
S |
p. S73
|
artikel
|
| 326 |
P-225: The optimal dose of thalidomide on the treatment of newly diagnosed multiple myeloma: real-world experience in Taiwan
|
Liao, Po Wei
|
|
|
22 |
S |
p. S159
|
artikel
|
| 327 |
P-191: The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review
|
Mian, Hira
|
|
|
22 |
S |
p. S140
|
artikel
|
| 328 |
P-227: The prognostic role of 1q21 gain/amp in newly diagnosed multiple myeloma: the faster, the worse
|
Wang, Yawen
|
|
|
22 |
S |
p. S160
|
artikel
|
| 329 |
P-205: The use of non cryopreserved peripheral blood stem cells in multiple myeloma: ten years experience from a single center in Algeria
|
Bekadja, Mohamed Amine
|
|
|
22 |
S |
p. S148
|
artikel
|
| 330 |
P-048: The value of autologous hematopoietic stem cell transplantation in multiple myeloma patients with MRD negative after early induction therapy
|
Liu, Jiahui
|
|
|
22 |
S |
p. S61-S62
|
artikel
|
| 331 |
P-118: Three distinct destines of malignant plasma cells based on single-cell transcriptomes and evolutionary trajectories
|
Xu, Jiadai
|
|
|
22 |
S |
p. S100
|
artikel
|
| 332 |
P-091: Thrombocytopenia with coagulation abnormality in multiple myeloma patients treated with proteasome inhibitor and/or immunomodulatory drugs
|
Suzuki, Kazuhito
|
|
|
22 |
S |
p. S85-S86
|
artikel
|
| 333 |
P-126: Thrombosis in multiple myeloma – risk estimation by induction regimen and association with overall survival
|
Charalampous, Charalampos
|
|
|
22 |
S |
p. S104-S104a
|
artikel
|
| 334 |
P-135: Time to event surrogate endpoints in multiple myeloma randomized trials from 2005-2019: a systematic review and surrogacy analysis
|
Etekal, Tommy
|
|
|
22 |
S |
p. S109
|
artikel
|
| 335 |
P-144: Treating multiple myeloma in a resourcelimited setting: real-world outcomes
|
Matinez, Gracia
|
|
|
22 |
S |
p. S114
|
artikel
|
| 336 |
P-261: Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
|
McCurdy, Arleigh
|
|
|
22 |
S |
p. S180-S181
|
artikel
|
| 337 |
P-274: Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
|
Huang, Jeffrey Shang-Yi
|
|
|
22 |
S |
p. S188-S189
|
artikel
|
| 338 |
P-265: Treatment patterns and outcomes of patients with triple-class exposed relapsed or refractory multiple myeloma: analysis of the Optum electronic health records and commercial claims database
|
Kumar, Shaji
|
|
|
22 |
S |
p. S183
|
artikel
|
| 339 |
P-254: Trends in attrition between first and second line therapy among older adults with multiple myeloma: a SEER-Medicare analysis
|
LeBlanc, Matthew
|
|
|
22 |
S |
p. S175-S176
|
artikel
|
| 340 |
P-283: TRIATLON - triple class exposed/refractory multipLe myeloma patients: a real world analysis (RWA) from the Austrian Myeloma Registry (AMR)
|
Willenbacher, Ella
|
|
|
22 |
S |
p. S193-S194
|
artikel
|
| 341 |
P-016: Tumor profiling of idecabtagene vicleucel (ide-cel, bb2121) patients in KarMMa showed comparable responses in existing molecular high-risk subsets and preliminary gene signature of durable response
|
Martin, Nathan
|
|
|
22 |
S |
p. S44-S45
|
artikel
|
| 342 |
P-115: Unc-51 Like Kinase 3 protein (ULK3)-mediated autophagy is responsible for multiple myeloma resistance to chemotherapy
|
Tauro, Marilena
|
|
|
22 |
S |
p. S98-S99
|
artikel
|
| 343 |
P-040: Unusual presentation of multiple myeloma with rapidly progressing lesions of the distal bones: about a case report
|
Lattenist, Raphaël
|
|
|
22 |
S |
p. S57-S57a
|
artikel
|
| 344 |
P-284: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
|
Yong, Kwee
|
|
|
22 |
S |
p. S194-S195
|
artikel
|
| 345 |
P-264: Updated results from LocoMMotion: A prospective, noninterventional, multinational study of real-life current standards-of-care in heavily pretreated patients with relapsed/refractory multiple myeloma
|
Moreau, Philippe
|
|
|
22 |
S |
p. S182-S183
|
artikel
|
| 346 |
P-189: Updated trial in progress: understanding treatment experience of individuals receiving isatuximab using both patient-reported outcomes and wearable data
|
Manasanch, Elisabet
|
|
|
22 |
S |
p. S139
|
artikel
|
| 347 |
P-174: Validation of Mayo Clinic 2018 and IMWG 2020 prognostic risk score for smoldering multiple myeloma (SMM), real world data; single center experience
|
Gkiokas, Alexandros
|
|
|
22 |
S |
p. S130-S131
|
artikel
|
| 348 |
P-142: Validation of new diagnostic criteria of primary plasma cell leukemia: a study of the Korean Multiple Myeloma Working Party (KMMWP-2003 study)
|
Jung, Sung-Hoon
|
|
|
22 |
S |
p. S113
|
artikel
|
| 349 |
P-162: Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study
|
Tan, Joanne
|
|
|
22 |
S |
p. S124
|
artikel
|
| 350 |
P-128: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry based M protein assessment
|
Claveau, Jean-Sebastien
|
|
|
22 |
S |
p. S105-S105a
|
artikel
|
Tijdschrift beschrijving